{
  "docId": "019de071-3fcc-709d-bd81-493d670a1b54",
  "docSlug": "75c0ef2784bf914c01a48398bea9ca14",
  "documentTitle": "Caribou Biosciences | IPO Presentation Deck | 44 slides",
  "authorId": "caribou-biosciences",
  "authorName": "Caribou Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7744917,
  "pageNumber": 43,
  "pageCount": 44,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a structured list format to highlight four key pillars of the company's value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3fcc-709d-bd81-493d670a1b54/43",
  "deckHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54",
  "deckJsonHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54.json",
  "deckAnchorHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.25,
        "y": 0.82
      },
      "kind": "image",
      "text": "Investor and partner logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2201734-2cde-46f5-bbcd-c1d64cd5cf10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.59
      },
      "kind": "list",
      "text": "Robust patent portfolio: Caribou owns >45 issued U.S. patents including 7 U.S. patents covering chRDNA technology; Caribou has exclusive rights to Cas12a chRDNAs for therapeutic applications and exclusive rights to Cas9 chRDNAs for CB-010",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b890c0c-a228-4594-92ca-071c60186734",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Allogeneic CAR-Ts & CAR-NKs: Initial focus on allogeneic CAR-T and CAR-NK cell therapies for oncology; Genome editing to enhance persistence; Lead product candidate CB-010 in Phase 1 study in r/r B-NHL; Pipeline includes allogeneic CAR-Ts for MM and AML",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6199f4d5-7d46-4be0-b5cd-9a50b06eb12d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Cutting-edge CRISPR platform: Founded by CRISPR pioneers, including Nobel Prize winner Jennifer Doudna; Proprietary chRDNA genome-editing platform; Enables broad potential range of therapeutic candidates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74d71139-672b-403c-be8b-7d4bbd15276c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "list",
      "text": "Backed by premier investors & strategic partner: Strategic collaboration with AbbVie; $115M Series C closed in March 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecf58560-8f21-4d04-bfdb-313fadb9e2ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Caribou has granted AbbVie an exclusive license to Cas12a chRDNAs for 2 CAR-T cell programs. 2. Series C: $115M gross proceeds, $109M net proceeds.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee8bc632-5578-4dd0-a603-91817c7e0c71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Proprietary chRDNA genome-editing technology enables therapies with significant potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d757609d-1ddf-4e40-8142-f0dea33f3630",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}